Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

NCT01269346 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eisai Inc.